John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $171.00.
John Newman’s rating is based on BioNTech SE’s promising clinical trial prospects and diversified oncology pipeline. The BNT-327 trial, which targets first-line non-small cell lung cancer (NSCLC), has a significantly larger sample size compared to Akeso’s HARMONi-2 study, enhancing the likelihood of achieving statistically significant results in overall survival benefits.
Additionally, BioNTech’s oncology portfolio is well-diversified, with ongoing investigations in various cancer types, including a Phase 2 trial for adjuvant colorectal cancer expected by late 2025 or early 2026. The company’s efforts in exploring its iNeST technology in the adjuvant settings of muscle-invasive urothelial carcinoma (MIUC) and pancreatic ductal adenocarcinoma (PDAC) further support the Buy rating, reflecting a strong potential for future growth and innovation.
In another report released today, Jefferies also maintained a Buy rating on the stock with a $149.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.